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Inﬂammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CaliforniaBACKGROUND & AIMS: Anti–tumor necrosis factor (anti-TNF)
therapies are the most widely used biologic drugs for treating
immune-mediated diseases, but repeated administration can
induce the formation of anti-drug antibodies. The ability to
identify patients at increased risk for development of anti-drug
antibodies would facilitate selection of therapy and use of
preventative strategies. METHODS: We performed a genome-
wide association study to identify variants associated with
time to development of anti-drug antibodies in a discovery
cohort of 1240 biologic-naïve patients with Crohn’s disease
starting inﬂiximab or adalimumab therapy. Immunogenicity
was deﬁned as an anti-drug antibody titer 10 AU/mL using a
drug-tolerant enzyme-linked immunosorbent assay. Signiﬁcant
association signals were conﬁrmed in a replication cohort of178 patients with inﬂammatory bowel disease. RESULTS: The
HLA-DQA1*05 allele, carried by approximately 40% of Euro-
peans, signiﬁcantly increased the rate of immunogenicity (haz-
ard ratio [HR], 1.90; 95% conﬁdence interval [CI], 1.60–2.25; P¼
5.88  10–13). The highest rates of immunogenicity, 92% at 1
year, were observed in patients treated with inﬂiximab mono-
therapy who carried HLA-DQA1*05; conversely the lowest rates
of immunogenicity, 10% at 1 year, were observed in patients
treated with adalimumab combination therapy who did not
carry HLA-DQA1*05. We conﬁrmed this ﬁnding in the replication
cohort (HR, 2.00; 95% CI, 1.35–2.98; P ¼ 6.60  10–4). This
association was consistent for patients treated with adalimumab
(HR, 1.89; 95% CI, 1.32–2.70) or inﬂiximab (HR, 1.92; 95% CI,
1.57–2.33), and for patients treated with anti-TNF therapy alone
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Anti-tumor necrosis factor (anti-TNF) therapies are the
most widely used biologic drugs for treating immune-
mediated diseases, but repeated administration can
induce the formation of anti-drug antibodies, increasing
the risk of treatment failure.
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AT(HR, 1.75; 95% CI, 1.37–2.22) or in combination with
an immunomodulator (HR, 2.01; 95% CI, 1.57–2.58).
CONCLUSIONS: In an observational study, we found a genome-
wide signiﬁcant association between HLA-DQA1*05 and the
development of antibodies against anti-TNF agents. A random-
ized controlled biomarker trial is required to determine
whether pretreatment testing for HLA-DQA1*05 improves pa-
tient outcomes by helping physicians select anti-TNF and com-
bination therapies. ClinicalTrials.gov ID: NCT03088449.NEW FINDINGS
In a genome-wide association study, we identiﬁed a
variant (HLA-DQA1*05) that increases risk of
development of antibodies against inﬂiximab and
adalimumab 2-fold in patients with Crohn’s disease,
regardless of concomitant immunomodulator use.Keywords: PANTS; GWAS; Loss Of Response; Drug Persistence.
nti–tumor necrosis factor (anti-TNF) therapies are
LIMITATIONS
The study was limited to patients of European descent,
40% of whom carry the risk allele.
IMPACT
Testing patients for HLA-DQA1*05 might help physicians
decide whether they should receive anti-TNF and
combination immunomodulator therapy.Athe most widely used biologics for treating immune-
mediated diseases and in 2018 accounted for a global
expenditure in excess of $23.5 billion.1 Repeated adminis-
tration often induces the formation of anti-drug antibodies
(immunogenicity), leading to treatment failure.2
Immunogenicity is more common in patients treated
with inﬂiximab (a murine-human chimeric monoclonal
antibody) than adalimumab (a fully human monoclonal
antibody) and is a major cause of low anti-TNF drug level,
infusion reactions, and non-remission in patients with
Crohn’s disease.2,3 Combination immunomodulator therapy
reduces the risk of immunogenicity to both adalimumab and
inﬂiximab, and for inﬂiximab, improves treatment out-
comes.2,4–6 Despite these beneﬁts, many patients are still
treated with anti-TNF monotherapy because of concerns
about the increased risk of adverse drug reactions, oppor-
tunistic infections, and malignancies associated with com-
bination therapy with immunomodulators.7–9
The ability to identify patients at increased risk of
immunogenicity may inﬂuence the choice of anti-TNF
treatment and the use of preventative strategies, including
combination therapy with immunomodulators. However,
our understanding of the cellular and molecular mecha-
nisms underpinning immunogenicity to biologics is limited.
Retrospective candidate gene studies have suggested vari-
ants in FCGR3A10 and HLA-DRB111,12 increase susceptibility
to immunogenicity to anti-TNF therapy. These associations
did not achieve genome-wide signiﬁcance and are yet to be
independently replicated. Here, we report the ﬁrst genetic
locus robustly associated with immunogenicity to anti-TNF
therapies.Abbreviations used in this paper: AIC, Akaike information criterion; CI,
conﬁdence interval; HR, hazard ratio; IBD, inﬂammatory bowel disease;
TNF, tumor necrosis factor; UC, ulcerative colitis.
Most current article
© 2020 by the AGA Institute. Published by Elsevier Inc. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
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The PANTS (Personalising Anti-TNF Therapy in Crohn’s
Disease) study is a United Kingdom–wide, multicenter, pro-
spective observational cohort reporting the treatment failure
rates of the anti-TNF drugs inﬂiximab (originator, Remicade
[Merck Sharp & Dohme, Hertfordshire, UK] and biosimilar, CT-
P13 [Celltrion, Incheon, South Korea]), and adalimumab
(Humira [AbbVie, Cambridge, MA]) in 1610 anti–TNF-naïve
patients with Crohn’s disease.2
At inclusion, subjects were aged 6 years or older and had
active luminal Crohn’s disease involving the colon and/or small
intestine. Choice of anti-TNF drug and use of concomitantimmunomodulator therapy was at the discretion of the treating
physician as part of usual care. Patients were initially studied
for 12 months or until drug withdrawal. In the ﬁrst year, study
visits were scheduled at ﬁrst dose, post-induction (weeks 12–
14), weeks 30 and 54, and at treatment failure. For inﬂiximab-
treated patients, additional visits occurred at each infusion.
After 12 months, patients were invited to continue follow-up
for an additional 2 years. Drug persistence was deﬁned as the
duration of time from initiation of anti-TNF therapy to exit from
the study due to treatment failure. Patients who exited the
study for other reasons, declined to participate in the 2-year
extension, or were lost to follow-up were censored at the
time of last drug dose or study visit.
At each visit, serum inﬂiximab or adalimumab drug and
anti-drug antibody levels were analyzed using total antibody
enzyme linked immunosorbent assays.13 See the
Supplementary Material for a detailed description of drug and
anti-drug antibody testing. The total antibody, unlike the more
commonly reported free antibody assay, includes a drug–
antibody disassociation step that allows the assessment of
anti-drug antibodies in the presence of drug. We deﬁned
immunogenicity as an anti-drug antibody concentration of 10
AU/mL, irrespective of drug level, at 1 or more time points.
DNA was extracted from pretreatment blood samples from
1524 individuals in the PANTS cohort and genotyping under-
taken using the Illumina CoreExome microarray (Illumina, San
Diego, CA). See the Supplementary Material for a detailed
description of the genetic analyses. We excluded individuals of
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see Supplementary Figure 1), 1 individual from each related
pair (deﬁned as a pi-hat >.187), and those with an outlying
number of missing or heterozygous genotypes. After quality
control, 1323 individuals remained in the study, of which
1240 had drug and anti-drug antibody level data available
(Supplementary Figure 2). With its case–control design, our
study had >80% power to detect genome-wide signiﬁcant
evidence of association (a ¼ 5  10–8) to variants with a
minor allele frequency >22% and a relative risk >1.4
(Supplementary Figure 3).14 Baseline demographics for these
patients are shown in Supplementary Table 1.
Variants with a genotype call rate of <95% or with signif-
icant evidence of deviation from Hardy-Weinberg equilibrium
(P < 1  10–10) were excluded. Single-nucleotide poly-
morphisms were imputed via the Sanger Imputation Service
using the Haplotype Reference Consortium panel, and
7,578,947 variants with an information content metric score
0.4 were subsequently taken forward for analysis.15 HLA
types were imputed at 2- and 4-digit resolution for the
following loci: HLA-A, HLA-C, HLA-B, HLA-DRB1, HLA-DQA1,
HLA-DQB1, and HLA-DPB1. Long-read sequencing of these HLA
alleles was undertaken to assess the accuracy of our
imputation.
We assembled an independent cohort to replicate signiﬁ-
cant ﬁndings from the discovery cohort. This comprised 107
Crohn’s disease, 64 ulcerative colitis, and 7 inﬂammatory bowel
disease (IBD)–type unclassiﬁed patients with cross-sectional
drug and anti-drug antibody levels measured as part of
routine clinical practice. The samples were genotyped using
either the Illumina CoreExome array (n ¼ 164)16 or the Affy-
metrix 500k array (n ¼ 14; ThermoFisher Scientiﬁc, Waltham,
MA).17 Quality control and imputation methods were the same
as in the discovery cohort.
Statistical Analysis
Rates of immunogenicity were estimated using the Kaplan-
Meier method. Clinical outcomes and genetic association tests
with time to anti-drug antibody development were performed
using multivariable Cox proportional hazards regression: sex,
drug type (inﬂiximab or adalimumab), immunomodulator use,
and the ﬁrst within-sample principal component were
included as covariates (Supplementary Table 2). Patients who
did not develop immunogenicity during the study were
censored at the point of last observation. Post-hoc sensitivity
analyses were undertaken to test our genetic ﬁndings with
immunogenicity, ﬁrstly, at progressively higher antibody
thresholds; secondly, to simulate a free-antibody assay; and
thirdly, excluding patients with a single anti-drug antibody
level 10 AU/mL and subsequent negative anti-drug anti-
bodies <10 AU/mL.
The Akaike information criterion (AIC) was used to
compare non-nested models to assess if the mode of inheri-
tance was dominant or additive, and to determine whether
HLA allele group, speciﬁc HLA alleles, or amino-acid sequence
best explained the association. The ﬁxed-effects Q statistic
was used to perform tests of heterogeneity of effect; this test
is an extension of Cochran’s Q-test and examines whether the
observed effect size variability is larger than expected by
chance. Interaction tests of the differential effects of drug
type (inﬂiximab vs adalimumab and Remicade [JanssenBiotech, Inc, Horsham, PA] vs CT-P13) and combination
therapy (immunomodulator vs no immunomodulator) condi-
tional on the genotype were performed. Mann-Whitney U
tests were used to compare serum levels of anti-drug anti-
bodies at week 54 stratiﬁed by anti-TNF drug and immuno-
modulator use.
Ethics
The South West Research Ethics committee approved the
study (Research Ethics Committee reference: 12/SW/0323) in
January 2013. Patients were included after providing informed,
written consent. The protocol is available online (www.
ibdresearch.co.uk).
Results
Within the ﬁrst 12 months, 44% of patients developed
anti-drug antibodies (95% conﬁdence interval [CI], 0.41–
0.48), and 62% of patients did so within 36 months (95% CI,
0.57–0.67). After correcting for immunomodulator use, the
rate of immunogenicity was greater in patients treated with
inﬂiximab (n ¼ 742) than adalimumab (n ¼ 498) (hazard
ratio [HR], 3.21; 95% CI, 2.61–3.95; P ¼ 1.18  10–28). In a
model including drug type as a covariate, rates of immuno-
genicity were greater in patients treated with anti-TNF
monotherapy (n ¼ 544) compared to combination therapy
with immunomodulators (n ¼ 696) (HR, 2.30; 95% CI, 1.94–
2.75; P < 6.10  10–21).
A Locus Within the HLA Region Is Associated
With Time to Immunogenicity
We identiﬁed a genome-wide signiﬁcant association on
chromosome 6 with time to development of immunoge-
nicity, with the most associated single-nucleotide poly-
morphism, rs2097432 (b38_pos: 6:32622994; HR, 1.70;
95% CI, 1.48–1.94; P ¼ 4.24  10–13), falling within the
major histocompatibility complex region (Figure 1 and
Supplementary Figures 4 and 5). We replicated this asso-
ciation in our independent cohort of 178 patients with IBD
(HR, 1.69; 95% CI, 1.26–2.28; P ¼ 8.80  10–4). A variant on
chromosome 11, rs12721026 (b38_pos: 11:116835452; HR,
0.46; 95% CI, 0.33–0.63; P ¼ 4.76  10–8) also reached
genome-wide signiﬁcance in our discovery analysis,
although the association was not replicated in our inde-
pendent cohort (HR, 0.85; 95% CI, 0.49–1.44; P ¼ .51).
Fine-Mapping of the Signal in the HLA Region
At the HLA allele group level (2-digit resolution), only
HLA-DQA1*05 achieved genome-wide signiﬁcance (HR,
1.90; 95% CI, 1.60–2.25; P¼ 5.88  10–13) (Figure 2). At the
speciﬁc allele level (4-digit resolution), no single allele
reached genome-wide signiﬁcance. The 2 most common
HLA-DQA1*05 subtype alleles, HLA-DQA1*05:01 (HR, 1.57;
95% CI, 1.33–1.85; P ¼ 4.24  10–7) and HLA-DQA1*05:05
(HR, 1.48; 95% CI, 1.24–1.78; P ¼ 5.54  10–5), had similar
effects on time to immunogenicity and a model containing
these two 4-digit alleles was virtually indistinguishable from
a model including HLA-DQA1*05 only (AIC05 ¼ 6659.07 vs
AIC05:01&05:05 ¼ 6659.50). We did not identify any amino
acids that better ﬁt the data than HLA-DQA1*05. We
Figure 1. A regional plot of the association results with the major histocompatibility complex (MHC) region on chromosome 6.
Midpoint positions of the HLA genes across the MHC region are shown in red on the x-axis. Single-nucleotide polymorphisms
(SNPs) that passed the genome-wide signiﬁcance threshold (P ¼ 5  10–8) are shown above the red horizontal dashed line with
the most signiﬁcant SNP in red. SNPs correlated with the lead SNP (r2 > 0.05) are color-coded from purple to yellow. Pairwise
genotype correlation (r2) between SNPs was calculated using genotype data from the non-Finnish European population of the
1000 Genomes Project.
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sequenced HLA genotypes at HLA-DQA1 (Supplementary
Table 3).
To formally assess the inheritance pattern of HLA-
DQA1*05 mediated immunogenicity, we compared the ﬁt
of additive and dominant models and found that the domi-
nant model gave a better ﬁt (AICDOM ¼ 6652.12 vs AICADD ¼
6659.07), and stronger association signal for HLA-DQA1*05
(HR, 1.90; 95% CI, 1.60–2.25; P ¼ 5.88  10–13) (Figure 3Figure 2. Effect sizes of the most strongly associated single-nu
on time to immunogenicity. Blue lines represent 95% CIs. Assoand Supplementary Table 4). We also looked for nonaddi-
tive effects across all other HLA alleles, but the model
assuming a dominant effect for HLA-DQA1*05 remained the
best ﬁt to the data. The HLA-DQA1*05 association was
conﬁrmed in our replication cohort (entire cohort (HR, 2.00;
95% CI, 1.35–2.98; P ¼ 6.60  10–4), Crohn’s disease-only
subset (HR, 2.26; 95% CI, 1.33–3.84; P ¼ .003), and ulcer-
ative colitis–only subset of the replication cohort (HR, 2.02;
95% CI, 1.08–3.79; P ¼ .03), again with a better ﬁt for thecleotide polymorphisms (SNPs), HLA alleles, and amino acids
ciation test P values are shown in parentheses.
Figure 3. Kaplan-Meier
estimator showing the rate
of anti-drug antibody
development, stratiﬁed by
the number of HLA-
DQA1*05 alleles carried.
Orange, blue, and red
indicate 0, 1, and 2 copies
of DQA1*05 allele,
respectively. Carriers of 1
or 2 copies of the allele
have a similar rate of
immunogenicity develop-
ment, and a dominant
model is a better ﬁt for the
data than an additive
model (AICDOM ¼ 6652.12
vs AICADD ¼ 6659.07). X-
axis truncated at 700 days,
due to the low number of
observations for longer
time periods.
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After conditioning on HLA-DQA1*05, we did not identify any
secondary signals of association with time to immunoge-
nicity within the major histocompatibility complex region
(Supplementary Figure 6).
Sensitivity analyses showed that the effect size of HLA-
DQA1*05 carriage on immunogenicity was similar across
subgroups (Figure 4A, 4B): ﬁrstly when the threshold for
deﬁning immunogenicity was increased from 10 AU/mL to
150 AU/mL. Secondly when we simulated a drug-sensitive
instead of a drug-tolerant assay, where immunogenicity was
deﬁned as an anti-drug antibody titer 10 AU/mL without
detectable drug (HR, 1.57; 95% CI, 1.23-2.01; P ¼ 3.66 
10–4). Thirdly when we removed patients with a one-off
transient anti-drug antibody level 10 AU/mL (HR, 1.94;
95% CI, 1.62–2.32; P ¼ 8.46  10–13).
The Effect of HLA-DQA1*05 Across Drug and
Treatment Regimes
While immunogenicity rates were lower with
adalimumab-treated compared to inﬂiximab-treated pa-
tients, we did not detect a signiﬁcant difference in the
effect of HLA-DQA1*05 on the immunogenicity rate for
these 2 drugs (HR, 1.89; 95% CI, 1.32–2.70 in adalimu-
mab-, HR, 1.92; 95% CI, 1.57–2.33 in inﬂiximab-treated
patients; Phet ¼ .91) (Figure 5). We also found no sig-
niﬁcant evidence for heterogeneity of effect of HLA-
DQA1*05 on immunogenicity between patients treated
with the inﬂiximab originator, Remicade, and its bio-
similar CT-P13 (Phet ¼ .23) (Supplementary Figure 7).
Likewise, we did not detect any signiﬁcant heterogeneity
of effect of HLA-DQA1*05 carriage on immunogenicity
for individuals on monotherapy (HR, 1.75; 95% CI,1.37–2.22) vs combination therapy (HR, 2.01; 95% CI,
1.57–2.58) with immunomodulators (Phet ¼ .14). In
addition, we did not identify any signiﬁcant interactions
between HLA-DQA1*05 and the clinical covariates (drug
type: P ¼ .83; mono- vs combination therapy: P ¼ .71;
Remicade vs CT-P13: P ¼ .59).
The highest rates of immunogenicity, 92% at 1 year,
were observed in patients treated with inﬂiximab mono-
therapy who carried HLA-DQA1*05 (Figure 6A).
Conversely, the lowest rates of immunogenicity, 10% at 1
year, were observed in patients treated with adalimumab
combination therapy who did not carry HLA-DQA1*05
(Figure 6B). Our ﬁnal model, which includes HLA-
DQA1*05 status, sex, drug, and immunomodulator usage,
explained 18% of the variance in immunogenicity to anti-
TNF in our cohort.
Having demonstrated that HLA-DQA1*05 was associated
with time to immunogenicity, we sought associations with
anti-drug antibody titers after 1 year of treatment and
subsequent non-persistence on drug. Carriage of HLA-
DQA1*05 was associated with higher maximal anti-drug
antibody titers (Pinﬂiximab ¼ 8  10–10; Padalimumab ¼ .002).
We observed lower drug persistence rates to year 3 in pa-
tients treated with an anti-TNF drug without an immuno-
modulator. HLA-DQA1*05 carriage was associated with
lower drug persistence only in patients treated with adali-
mumab without an immunomodulator (Figure 7A, 7B); the
optimal model here used the interaction between immu-
nomodulator use and HLA-DQA1*05 (DQA1*05: HR, 1.40;
95% CI, 1.08–1.80; P ¼ .011, immunomodulator use: HR,
0.74; 95% CI, 0.58–0.94; P ¼ .014, interaction between
DQA1*05 and immunomodulator use: HR, 0.65; 95% CI,
0.45–0.95; P ¼ .026).
Figure 4. (A) Sensitivity
analysis of the effect size
of DQA1*05 association
and time to immunoge-
nicity. (B) Sensitivity anal-
ysis of the signiﬁcance of
DQA1*05 association and
time to immunogenicity. In
the primary analyses,
immunogenicity was
deﬁned as an anti-drug
antibody concentration
10 AU/mL, irrespective
of drug concentration (red
dot). We repeated the time
to immunogenicity anal-
ysis varying this deﬁnition
from 5 to 200 AU/mL.
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Immunogenicity to biologic therapies is a major
concern for patients, regulatory authorities, and the
pharmaceutical industry. We report the ﬁrst genome-
wide signiﬁcant association with immunogenicity to
anti-TNF therapy using the largest prospective cohort
study of inﬂiximab and adalimumab in Crohn’s disease.
We have demonstrated that carriage of 1 or more
HLA-DQA1*05 alleles confers an almost 2-fold risk of
immunogenicity to anti-TNF therapy, irrespective ofconcomitant immunomodulator use or drug type (inﬂix-
imab [Remicade or CT-P13] or adalimumab). Fine-
mapping and conﬁrmatory sequencing of the HLA
identiﬁed that the speciﬁc alleles HLA-DQA1*05:01 and
HLA-DQA1*05:05 mediated most of this risk. Carriage of
HLA-DQA1*05 was associated with higher anti-drug
antibody levels and lower drug persistence rates,
although further studies are needed to more accurately
quantify the relationship between HLA-DQA1*05 and the
risk of anti-TNF treatment failure.
Figure 5. HLA-DQA1*05 has a consistent effect on immunogenicity in different patient subgroups. We repeated the propor-
tional hazard association analysis, separating the full cohort into subgroups by drug and therapy type. Estimated HRs and SEs
between the pairings were compared using a heterogeneity of effects test (P > .05), suggesting that the effect of DQA1*05 on
immunogenicity is not affected by these clinical covariates. Blue lines represent 95% CIs. Association test P values are shown
in parentheses.
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ease, all patients treated with an anti-TNF should be pre-
scribed an immunomodulator to lower the risk of
immunogenicity. We hypothesize that for patients who carry
HLA-DQA1*05 in whom immunomodulators are contra-
indicated or not tolerated, clinicians might advise against
the use of anti-TNF drugs, particularly inﬂiximab. This is
because 90% of patients who carry HLA-DQA1*05 who are
treated with inﬂiximab monotherapy have evidence of
immunogenicity by week 54. In contrast, patients who do
not carry HLA-DQA1*05 might be given the choice between
adalimumab or inﬂiximab combination therapy. Patients
without the risk allele and a history of adverse drug re-
actions to thiopurines and/or methotrexate, or who are at
high risk of opportunistic infections, might be spared the
additional risks of combination therapy and treated with
adalimumab monotherapy. A randomized controlled
biomarker trial is required to explore these hypotheses and
conﬁrm whether HLA-DQA1*05 testing may help direct
treatment choices in order to improve clinical outcomes.
The shared genetic association between HLA-DQA1*05
and immunogenicity to inﬂiximab and adalimumab may
explain the widely reported diminishing returns of switch-
ing between anti-TNF therapies at the time of loss of
response.18,19 If the immunogenic effect of HLA-DQA1*05
extends to other therapeutic antibodies, then subjects who
carry the variant may be candidates for non-antibody mo-
dality therapies, such as small molecule drugs. Allelic vari-
ation in the HLA-DQA1 gene has been linked to aberrant
adaptive immune responses. The HLA class II gene
HLA-DQA1 is expressed by antigen presenting cells and
encodes the a-chain of the HLA-DQ heterodimer that forms
part of the antigen-binding site where epitopes are pre-
sented to T-helper cells. Relevant to immunogenicity, car-
riage of HLA-DQA1*05 has been associated with celiacdisease, type 1 diabetes, and protection against rheumatoid
arthritis and pulmonary tuberculosis.20–24 Several hypoth-
eses have been proposed, but exactly how speciﬁc HLA al-
leles contribute to disease pathogenesis or, in this case,
increased immunogenicity, remains unknown.
HLA-DQ1A*05 may serve as a useful biomarker of
immunogenicity risk and may impact how the next-
generation of anti-TNF drugs are designed to minimize
HLA-DQA1*05 mediated immunogenicity. Previous studies
have shown that it is possible to map and eliminate po-
tential immunogenic T-cell epitopes with the aim of pro-
ducing safer and more durable biologic drugs.25,26 However,
caution needs to be exercised to ensure protein sequence
modiﬁcations designed to reduce the risk of immunoge-
nicity to patients carrying HLA-DQA1*05 do not put a
different group of patients at risk.
Multiple assays are available to detect anti-drug anti-
bodies and there is no universally accepted, validated
threshold to diagnose immunogenicity. We deliberately
chose a total or drug-tolerant assay that permits the mea-
surement of anti-drug antibodies in the presence of drug in
order to minimize the number of false-negative patients
assigned to the control group. We then validated the man-
ufacturer’s positivity threshold in independent experiments
in 500 drug-naïve controls and conﬁrmed that the recom-
mend cutoff of 10 AU/mL corresponds to the 99th centile of
the anti-drug antibody titer distribution. In support of this
threshold, we have recently demonstrated that even
modestly elevated anti-drug antibodies levels (10–30 AU/
mL) at weeks 14 and 54 of treatment are associated with
lower drug levels at these time points, and non-remission at
week 54.2 In addition, sensitivity analyses conﬁrmed that
the association and effect size between HLA-DQA1*05 and
immunogenicity remained at progressively higher diag-
nostic thresholds for immunogenicity, when we simulated a
Figure 6. (A) Anti-drug
antibody development—
inﬂiximab. (B) Anti-drug
antibody development—
adalimumab. Kaplan-
Meier estimator showing
the rate of anti-drug anti-
body development (A, B)
stratiﬁed by carriage of
HLA-DQA1*05 alleles and
treatment regime. Dotted
lines indicate patients un-
dergoing anti-TNF mono-
therapy; solid lines
indicate combination ther-
apy with immunomodula-
tors. Red indicates carriers
of the HLA-DQA1*05 allele
(1 or 2 copies); blue in-
dicates noncarriers. For
both drugs and treatment
regimes, immunogenicity
rates are higher for HLA-
DQA1*05 carriers. The x-
axis was truncated at 700
days due to the low num-
ber of observations.
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antibodies. Finally, HLA-DQA1*05 was associated with the
quantitative trait of maximal anti-drug antibody titer.
We acknowledge several important limitations of this
study. Firstly, we may have underestimated the contribution
of HLA-DQA1*05 to immunogenicity because of the short
duration of follow-up in patients who did not continue in
the study beyond the ﬁrst year. Secondly, because we
designed a schedule of visits to minimize patients’ incon-
venience, there were fewer assessments for those treated
with adalimumab than inﬂiximab. As a result, we might haveunderestimated rates of immunogenicity among
adalimumab-treated patients.
Our genome-wide association study was limited to pa-
tients with luminal Crohn’s disease of European descent.
Given that HLA-DQA1*05 is not associated with Crohn’s
disease risk,27 the percentage of carriers among our patients
(39%) was similar to that reported in an independent
British population cohort (38%).28 As such, we hypothesize
that HLA-DQA1*05 will make a similar contribution to anti-
TNF immunogenicity in other patient populations where
the allele is not associated with disease susceptibility
Figure 7. (A) Drug persis-
tence—inﬂiximab. (B) Drug
persistence—adalimumab.
Kaplan-Meier estimator
showing the rate of drug
persistence (A, B) stratiﬁed
by carriage of HLA-
DQA1*05 alleles and
treatment regime. Dotted
lines indicate patients un-
dergoing anti-TNF mono-
therapy; solid lines
indicate combination ther-
apy with immunomodula-
tors. Red indicates carriers
of the HLA-DQA1*05 allele
(1 or 2 copies); blue in-
dicates noncarriers. The x-
axis was truncated at 700
days due to the low num-
ber of observations.
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Due to the wide variation in the frequency of HLA-DQA1*05
across ethnic groups,28 further studies are required to
assess the contribution of HLA-DQA1*05 to immunogenicity
across populations. Whether HLA-DQA1*05 is also associ-
ated with immunogenicity to other biologic drugs also needs
to be determined.
We report the ﬁrst genome-wide signiﬁcant association
with immunogenicity to biologic drugs. Carriage of HLA-
DQA1*05 almost doubles the rate of anti-TNF anti-drug
antibody development, independent of immunomodulatoruse, for both inﬂiximab and adalimumab. To minimize the
risk of immunogenicity, pretreatment genetic testing for
HLA-DQA1*05 may help personalize the choice of anti-TNF
and the need for combination therapy with an
immunomodulator.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
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